Analyst Price Targets — GRDN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 12, 2026 8:55 pm | John Ransom | Raymond James | $40.00 | $33.27 | StreetInsider | Guardian Pharmacy Services Inc. (GRDN) PT Raised to $40 at Raymond James |
| March 12, 2026 11:11 am | David MacDonald | Truist Financial | $38.00 | $34.47 | StreetInsider | Guardian Pharmacy Services Inc. (GRDN) PT Raised to $38 at Truist on 'Strong Close To '25' |
| January 14, 2026 11:47 am | Raj Kumar | Stephens | $36.00 | $31.26 | TheFly | Guardian Pharmacy price target raised to $36 from $35 at Stephens |
| November 14, 2025 2:28 pm | — | Truist Financial | $34.00 | $29.51 | TheFly | Guardian Pharmacy price target raised to $34 from $30 at Truist |
| October 10, 2025 10:21 am | — | Oppenheimer | $30.00 | $23.68 | TheFly | Guardian Pharmacy initiated with an Outperform at Oppenheimer |
| September 26, 2025 1:19 pm | David MacDonald | Truist Financial | $30.00 | $25.68 | TheFly | Guardian Pharmacy price target raised to $30 from $28 at Truist |
| May 14, 2025 12:11 pm | John Ransom | Raymond James | $28.00 | $24.12 | TheFly | Guardian Pharmacy price target raised to $28 from $25 at Raymond James |
Latest News for GRDN
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 6, 2026. Management will host a conference call to discuss the results at 4:30 p.m. Eastern Time. Conference Call Details The conference call will be available via audio webcast at https://investors.guardianpharmacy.com and can also be…
GRDN and ESCA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 10th, 2026.
ESCA, GRDN, TPST, ASTE and ECG have been added to the Zacks Rank #1 (Strong Buy) List on April 10th, 2026.
Guardian Pharmacy Services (GRDN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Guardian Pharmacy (GRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GRDN.
U.S. House Trading
No House trades found for GRDN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.